The gist of GSK's move is to follow Ono
The UK company buys IRDx for $1bn.
Here comes another PD-1/VEGF bispecific
OncoC4’s AI-081 features among the industry’s latest first-in-human trial initiations.
The UK company buys IRDx for $1bn.
OncoC4’s AI-081 features among the industry’s latest first-in-human trial initiations.
